Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: A 3-year randomized trial

JAMA

Volumn 292, Issue 2, 2004, Pages 191-201

  Gallant, Joel E ^a   Staszewski, Schlomo ^b   Pozniak, Anton L ^c   DeJesus, Edwin ^d   Suleiman, Jamal M A H ^e   Miller, Michael D ^f   Coakley, Dion F ^f   Lu, Biao ^f   Toole, John J ^f   Cheng, Andrew K ^f  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^d Infect Dis Consult Res I   (United States)

^e INSTITUTO DE INFECTOLOGIA EMÍLIO RIBAS   (Brazil)

^f GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLASE; CHOLESTEROL; CREATINE KINASE; CREATININE; EFAVIRENZ; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LAMIVUDINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR DISOPROXIL; TRIACYLGLYCEROL; VIRUS RNA; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DRUG DERIVATIVE; ORGANOPHOSPHORUS COMPOUND; OXAZINE DERIVATIVE; PHOSPHONIC ACID DERIVATIVE; TENOFOVIR;

ADULT; ARTICLE; BACTERIAL INFECTION; BONE DENSITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EUROPE; FEMALE; FEVER; FRACTURE; GLUCOSURIA; HEMATURIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOPHOSPHATEMIA; KIDNEY DYSFUNCTION; LACTIC ACIDOSIS; LIPID BLOOD LEVEL; LIPODYSTROPHY; LIVER DYSFUNCTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPPORTUNISTIC INFECTION; PERIPHERAL NEUROPATHY; PNEUMONIA; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RASH; SOUTH AMERICA; STATISTICAL ANALYSIS; UNITED STATES; VIRUS LOAD; VIRUS MUTATION; VIRUS RESISTANCE; ANTIBIOTIC RESISTANCE; COMPARATIVE STUDY; GENETICS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS 1; MIDDLE AGED; PROSPECTIVE STUDY;

ADENINE; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DOUBLE-BLIND METHOD; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; ORGANOPHOSPHORUS COMPOUNDS; OXAZINES; PHOSPHONIC ACIDS; PROSPECTIVE STUDIES; STAVUDINE; VIRAL LOAD;

EID: 3042848853     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.292.2.191     Document Type: Article

References (44)

1. Hogg RS, O'Shaughnessy MV, Gataric N, et al. Decline in deaths from AIDS due to new antiretrovirals. Lancet. 1997;349:1294.
2. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853-860.
3. Wit FW, van Leeuwen R, Weverling GJ, et al. Outcome and predictors of failure of highly active antiretroviral therapy. J Infect Dis. 1999;179:790-798.
4. Stone VE. Strategies for optimizing adherence to highly active antiretroviral therapy. Clin Infect Dis. 2001;33:865-872.
5. Spire V, Cailleton V, Carrieri P, et al. Dynamic of adherence to antiretroviral therapy and its impact on virological and immunological response after 3 years of treatment. In: Program and abstracts of the XIV International AIDS Conference; July 7-12, 2002; Barcelona, Spain. Abstract Th.Pe.B.2137.
6. Ledergerber B, Egger M, Opravil M, et al. Clinical progressions and virological failure on highly active antiretroviral therapy in HIV-1 patients. Lancet. 1999; 353:863-868.
7. Dieterich DT. Long-term complications of nucleoside reverse transcriptase inhibitor therapy. AIDS Read. 2003;13:176-187.
8. Brinkman K, Smeitink JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet. 1999;354:1112-1115.
9. Fung HB, Stone EA, Piacenti FJ. Tenofovir disoproxil fumarate. Clin Ther. 2002;24:1515-1548.
10. Grim SA, Romanelli F. Tenofovir disoproxil fumarate. Ann Pharmacother. 2003;37:849-859.
11. Gallant JE, Deresinski S. Tenofovir disoproxil fumarate. Clin Infect Dis. 2003;37:944-950.
12. Birkus G, Hitchcock MJM, Cihlar T. Assessment of mitochondrial toxicity in human cells treated with tenofovir. Antimicrob Agents Chemother. 2002;46: 716-723.
13. Louie M, Hogan C, Hurley A, et al. Determining the antiviral activity of tenofovir disoproxil fumarate in treatment-naive chronically HIV-1-infected individuals. AIDS. 2003;17:1151-1156.
14. Schooley RT, Ruane P, Myers RA, et al. Tenofovir DF in antiretroviral-experienced patients. AIDS. 2002;16:1257-1263.
15. Squires K, Pozniak AL, Pierone G, et al. Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection. Ann Intern Med. 2003;139:313-320.
16. Cheng, A, Chen SS, Wulfsohn M, Toole JJ. 2 year long term safety profile of tenofovir DF in treatment-experienced patients from randomized, placebo-controlled clinical trials. In: Program and abstracts of the 9th European AIDS Conference; October 25-29, 2003; Warsaw, Poland. Abstract 7.3/7.
17. Margot NA, Isaacson E, McGowan I, et al. Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF. AIDS. 2002;16:1227-1235.
18. Margot NA, Isaacson E, McGowan I, et al. Extended treatment with tenofovir disoproxil furnarate in treatment-experienced HIV-1-infected patients. J Acquir Immune Defic Syndr. 2003;33:15-21.
19. Staszewski S, Gallant JE, Pozniak AL, et al. Efficacy and safety of tenofovir DF (TDF) versus stavudine (d4T) when used in combination with lamivudine and efavirenz in antiretroviral naive patients: 96-week preliminary interim results. In: 10th Conference on Retroviruses and Opportunistic Infections; February 10-14, 2003; Boston, Mass. Abstract 564b.
20. Dore GJ, Cooper DA, Pozniak AL, et al. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naïve and -experienced patients coinfected with HIV-1 and hepatitis B virus. J Infect Dis. 2004; 189:1185-1192.
21. Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available at: http://aidsinfo.nih.gov. Accessibility verified June 15, 2004.
22. van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine. Lancet. 2004;363: 1253-1263.
23. Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health. DAIDS Table for grading severity of adult adverse experiences: Adult AIDS Clinical Trials Group. Available at: http://aactg.s-3.com. Accessibility verified June 15, 2004.
24. Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med. 1999;341:1865-1873.
25. Staszewski S, Keiser P, Montaner J, et al. Abacavirlamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral naïve HIV infected adults. JAMA. 2001;285:1155-1163.
26. Larder BA, et al. Quantitative prediction of HIV-1 drug resistance from genotypes. Antivir Ther. 2000;5 (suppl 3):49.
27. Petropoulos CJ, Parkin NT, Limoli KL, et al. A novel phenotypic drug susceptibility assay for HIV-1. Antimicrob Agents Chemother. 2000;44:920-928.
28. Tisdale M, Alnadaf T, Cousens D. Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89. Antimicrob Agents Chemother. 1997;41:1094-1098.
29. Harrigan PR, Stone C, Griffin P, et al. Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy. J Infect Dis. 2000;181:912-920.
30. Winters MA, Shafer RW, Jellinger RA, et al. Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years. Antimicrob Agents Chemother. 1997;41:757-762.
31. Gu Z, Fletcher RS, Arts EJ, et al. The K65R mutant reverse transcriptase of HIV-1 cross-resistant to 2′,3′-dideoxycytidine, 2′,3′-dideoxy-3′-thiacytidine, and 2′,3′- dideoxyinosine shows reduced sensitivity to specific dideoxynucleoside triphosphate inhibitors in vitro. J Biol Chem. 1994;269: 28118-28122.
32. Wainberg MA, Miller MD, Quan Y, et al. In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA. Antiviral Therapy. 1999;4: 87-94.
33. Miller MD, McColl DJ, White KL, Parkin NT. Genotypic characterization of patient-derived HIV-1 isolates containing the K65R mutation in reverse transcriptase. In: 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; September 14-17, 2003; Chicago, Ill. Poster H-904.
34. Bazmi HZ, Hammond JL, Cavalcanti SC, et al. In vitro selection of mutations in the human immunodeficiency virus type 1 reverse transcriptase that decrease susceptibility to (-)-β-D-dioxolane-guanosine and suppress resistance to 3′-azido-3′-deoxythymidine. Antimicrob Agents Chemother. 2000;44:1783-1788.
35. White KL, Margot NA, Wrin T, et al. Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme function and viral replication capacity. Antimicrob Agents Chemother. 2002;46:3437-3446.
36. Gallant JE, Pozniak AL, Staszewski S, et al. Similar 96-week renal safety profile of tenofovir disoproxil fumarate (TDF) versus stavudine (d4T) when used in combination with lamivudine (3TC) and efavirenz (EFV) in antiretroviral naive patients. In: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 14-17, 2003; Chicago, III. Abstract H-840.
37. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition of AIDS among adolescents and adults. MMWR Recomm Rep. 1992; 41(RR-17):1-19.
38. Domingo P, Labargo P, Palacios R, et al. Improvement of dyslipidemia in patients switching from stavudine to lamivudine: preliminary results. AIDS. 2004; 18:1475-1478.
39. Carr A, Workman C, Smith DE, et al. Abacavir substitution for nucleoside analogues in patients with HIV lipoatrophy. JAMA. 2002;288:207-215.
40. Carr A, Workman C, Carey D, et al. No effect of rosiglitazone for treatment of HIV-1 lipoatrophy. Lancet. 2004;363:429-438.
41. Reynes J, Peyriere H, De Boever CM, Le Moing V. Renal tubular injury and severe hypophosphoremia (Fanconi syndrome) associated with tenofovir therapy. In: 10th Conference on Retroviruses and Opportunistic Infections; February 10-14, 2003; Boston, Mass. Abstract 717.
42. Blick G, Grieger-Zanlungo, Garton T, et al. Tenofovir may cause severe hypophosphatemia in HIV/AIDS patients with prior adefovir-induced renal tubular acidosis. In: 10th Conference on Retroviruses and Opportunistic Infections; February 10-14, 2003; Boston, Mass. Abstract 718.
43. Karras A, Lafaurie M, Furco A, et al. Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients. Clin Infect Dis. 2003;36:1070-1073.
44. Fischl M, Castro J, Monroig R, et al. Impact of directly observed therapy on long-term outcomes in HIV clinical trials. In: Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections; February 4-8, 2001; Chicago, Ill. Abstract 528.